NTT
18.12.2019 07:55:13 CET | Business Wire | Press release
In recent times, there has been a growing demand for companies worldwide to strengthen their compliance and risk management. To help our clients manage these requirements, NTT Group, represented by NTT Advanced Technology Corporation (hereinafter, NTT-AT), Everis Spain S.L.U. (hereinafter, everis) of NTT DATA Corporation, itelligence AG (hereinafter, itelligence) of NTT DATA Corporation are announcing a compliance management solution using robotic process automation (RPA). This solution aggregates and analyses data from internal HR and compliance on-premise and cloud-based systems, supporting customer initiatives to strengthen responsibility and internal governance control. The NTT Group plans to start providing this service in the second quarter of 2020.
Due to stricter regulations across many industries, particularly the financial industry, businesses are facing the threat of multi-regime controls and high fines by local authorities. Due to the complexity of the regulations and reporting requirements, these institutions are facing problems to identify compliance issues, along with a lack of transparency in governance. This often leads to increased manual workload, process time and paperwork due to the complexity of their IT environment.
The integrated solution provided by NTT Group combines; the RPA tool "WinActor ® (*1) " of NTT-AT, the SMCR solution of everis, and the consulting and the integration capabilities of itelligence to achieve the combination of reducing complex manual operations and coordination of compliance-related data managed across multiple systems, such as Excel (*2) and existing systems.
This solution will initially be provided as a compliance management solution for the “Senior Managers and Certification Regime (SMCR)" in the UK and will be expanded outside the UK in response to regulations and to support clients compliance and governance management globally.
NTT helps its clients accelerate their digital transformation journey by implementing innovative technologies, such as WinActor® .
Notes:
About "WinActor®
"
WinActor is a robotic process automation (RPA) tool which has been developed using the in-house technologies by NTT Access Network service system laboratories and has been achieved into commercialization.
WinActor records and automates various types of human operations such as those via Windows (*2)
application, Web Application and so on. It runs automatically routine repetitive tasks and large volume works instead of or collaborating with human. Additionally, by changing the existing jobs into new automatic work style, it would bring out a large value in business perspective such as efficiency, quality and cost effectiveness without modifying any software of existing system.
WinActor has been rapidly introduced and spread since 2017 especially in the organizations which seek for “Work style revolution” regardless the type of industry and size of the company. Currently, in November end of 2019, more than 4,200 companies have introduced WinActor.
For more information, please refer to https://winactor.biz/
.
(*1) "WinActor" is a registered trademark of NTT Advanced Technology Corporation.
(*2) "Excel", “Windows” is registered trademarks or trademarks of Microsoft Corporation in the US and/or other countries.
About NTT
For more information on NTT, visit www.global.ntt/
For more information on NTT-AT, visit www.ntt-at.com/
For more information on everis, visit www.everis.com/global/en
For more information on itelligence, visit itelligencegroup.com/us/
For more information on the solution, visit uk.nttdata.com/SMCR
View source version on businesswire.com: https://www.businesswire.com/news/home/20191217005950/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wyss Geneva Steps Into Its Next Chapter11.6.2026 13:33:00 CEST | Press release
Dr. Tracy Laabs named Director; Prof. Dr. Erwin Böttinger honored for his transformative leadership The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simult
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 13:24:00 CEST | Press release
Nearly two-thirds of patients aged 80+ treated with BRUKINSA remained progression-free at six years, despite advanced age and high-risk featuresNew European patient research reveals safety, disease severity, and effectiveness are the top drivers for first-line CLL treatment decisions – not time on therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D.,
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 13:00:00 CEST | Press release
Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study More than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib Safety profile was consistent with previous studies with no new safety signals identified Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrate
Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 13:00:00 CEST | Press release
Transaction adds 31 CLOs and more than $5 billion of AUM, strengthening Clearlake Credit’s position in liquid credit Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction
L&T Technology Services, Databricks Partner to Deliver Industrial AI at Scale for Asset-Intensive Industries11.6.2026 12:30:00 CEST | Press release
Partnership brings together LTTS’ expertise in its Sustainability segment and the Databricks platform to accelerate Engineering Intelligence across industrial operations. L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a strategic go-to-market partnership with Databricks, the leading Data and AI company, to co-develop and deliver Industrial AI solutions that advance Engineering Intelligence (EI) for asset-intensive enterprises. Anchored in LTTS' Sustainability segment, spanning Process Engineering, Discrete Manufacturing and Industrial Products, the partnership will support Energy, Petrochemicals and Industrials clients globally. As industrial organizations seek to unlock greater value from decades of operational and engineering data, the alliance will combine LTTS’ deep domain capabilities with the Databricks platform to transform complex plant data into Engineering Intelligence - enabling improved asset reli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom